383 related articles for article (PubMed ID: 12895320)
1. [The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].
Yao GB; Wang BE; Cui ZY; Yao JL; Zeng MD
Zhonghua Nei Ke Za Zhi; 2003 Jun; 42(6):382-7. PubMed ID: 12895320
[TBL] [Abstract][Full Text] [Related]
2. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
3. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
4. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
5. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
Yao G; Wang B; Cui Z; Yao J; Zeng M
Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504
[TBL] [Abstract][Full Text] [Related]
7. [Long-term effect of lamivudine treatment in chronic hepatitis B virus infection].
Yao G; Wang B; Cui Z
Zhonghua Gan Zang Bing Za Zhi; 1999 Jun; 7(2):80-3. PubMed ID: 10488413
[TBL] [Abstract][Full Text] [Related]
8. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
9. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
10. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
11. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
12. [Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study].
Yao GB; Cui ZY; Yao JL; Zhang DF; Ji NX; Huang Y
Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):103-8. PubMed ID: 12648409
[TBL] [Abstract][Full Text] [Related]
13. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy of lamivudine in the treatment of chronic hepatitis B].
Ma H; You H; Yin S
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Jun; 15(2):147-9. PubMed ID: 11436644
[TBL] [Abstract][Full Text] [Related]
15. [Optimal lamivudine treatment duration and the relationship between its early response and long term effect].
He YW; Guo CX; Pan YF; Li SL; Wang H
Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):902-5. PubMed ID: 17196133
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
[TBL] [Abstract][Full Text] [Related]
17. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
18. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
20. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]